Tomivosertib

Generic Name
Tomivosertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C17H20N6O2
CAS Number
1849590-01-7
Unique Ingredient Identifier
U2H19X4WBV
Background

Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Procedure: Biospecimen Collection
Drug: Tomivosertib
First Posted Date
2023-02-27
Last Posted Date
2024-07-19
Lead Sponsor
Northwestern University
Target Recruit Count
15
Registration Number
NCT05744739
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Fox Chase, Philadelphia, Pennsylvania, United States

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

First Posted Date
2020-11-09
Last Posted Date
2024-04-30
Lead Sponsor
Effector Therapeutics
Target Recruit Count
68
Registration Number
NCT04622007
Locations
🇺🇸

Texas Oncology - Memorial City, Houston, Texas, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Ventura - UCLA, Ventura, California, United States

and more 137 locations

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
Drug: tomivosertib
Drug: paclitaxel
First Posted Date
2020-02-07
Last Posted Date
2022-07-20
Lead Sponsor
Translational Research in Oncology
Target Recruit Count
19
Registration Number
NCT04261218
Locations
🇨🇦

Jewish General Hospital, Montreal, Quebec, Canada

🇨🇦

British Columbia Cancer Vancouver, Vancouver, British Columbia, Canada

🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy